Virbac Sa Stock Current Valuation
| VIRP Stock | EUR 324.00 3.00 0.93% |
Valuation analysis of Virbac SA helps investors to measure Virbac SA's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Virbac SA's price fluctuation is very steady at this time. Calculation of the real value of Virbac SA is based on 3 months time horizon. Increasing Virbac SA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Virbac SA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Virbac Stock. However, Virbac SA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 324.0 | Real 286.65 | Hype 324.0 | Naive 328.33 |
The real value of Virbac Stock, also known as its intrinsic value, is the underlying worth of Virbac SA Company, which is reflected in its stock price. It is based on Virbac SA's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Virbac SA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Virbac SA helps investors to forecast how Virbac stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Virbac SA more accurately as focusing exclusively on Virbac SA's fundamentals will not take into account other important factors: Virbac SA Company Current Valuation Analysis
Virbac SA's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Virbac SA Current Valuation | 2 B |
Most of Virbac SA's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Virbac SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Virbac SA has a Current Valuation of 2 B. This is 86.08% lower than that of the Healthcare sector and 98.9% lower than that of the Drug Manufacturers - Major industry. The current valuation for all France stocks is 87.98% higher than that of the company.
Virbac Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Virbac SA's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Virbac SA could also be used in its relative valuation, which is a method of valuing Virbac SA by comparing valuation metrics of similar companies.Virbac SA is currently under evaluation in current valuation category among its peers.
Virbac Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.091 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 2 B | |||
| Shares Outstanding | 8.44 M | |||
| Shares Owned By Insiders | 50.38 % | |||
| Shares Owned By Institutions | 25.03 % | |||
| Price To Earning | 70.83 X | |||
| Price To Book | 2.47 X | |||
| Price To Sales | 1.76 X | |||
| Revenue | 1.06 B | |||
| Gross Profit | 712.85 M | |||
| EBITDA | 201.66 M | |||
| Net Income | 113.16 M | |||
| Cash And Equivalents | 63.55 M | |||
| Cash Per Share | 7.55 X | |||
| Total Debt | 13.15 M | |||
| Debt To Equity | 98.40 % | |||
| Current Ratio | 1.23 X | |||
| Book Value Per Share | 96.99 X | |||
| Cash Flow From Operations | 129.9 M | |||
| Earnings Per Share | 14.05 X | |||
| Target Price | 311.6 | |||
| Number Of Employees | 5.12 K | |||
| Beta | 0.88 | |||
| Market Capitalization | 2.4 B | |||
| Total Asset | 1.2 B | |||
| Retained Earnings | 163 M | |||
| Working Capital | 122 M | |||
| Current Asset | 486 M | |||
| Current Liabilities | 364 M | |||
| Annual Yield | 0 % | |||
| Five Year Return | 1.09 % | |||
| Net Asset | 1.2 B | |||
| Last Dividend Paid | 1.25 |
About Virbac SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Virbac SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virbac SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virbac SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Virbac Stock
Virbac SA financial ratios help investors to determine whether Virbac Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Virbac with respect to the benefits of owning Virbac SA security.